| ￥3300 | |
| Z05875-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 78.4 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 78.4 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM Tris, 500mM NaCl, 10% Glycerol (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Transglutaminase 2 (TGM2) is a member of the transglutaminase family, and it is reported to be associated with chemoresistance in various types of cancer. TGM2 was demonstrated to affect the chemosensitivity of osteosarcoma cells via regulation of the activation of mitogen‑activated protein kinase and AKT serine/threonine kinase pathways. |
| Synonyms | TGM2; tTG; tTgase; TGC; TGase C; TGase II; TG2; G-ALPHA-h; GNAH; HEL-S-45; TGase-2; TGase-H; TGCGNAH |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
